Herve P - Search Results

1

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G. Sitbon O, et al. Among authors: herve p. Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):384-9. doi: 10.1164/ajrccm.151.2.7842196. Am J Respir Crit Care Med. 1995. PMID: 7842196 Clinical Trial.

2

Increased plasma serotonin in primary pulmonary hypertension.

Hervé P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L. Hervé P, et al. Am J Med. 1995 Sep;99(3):249-54. doi: 10.1016/s0002-9343(99)80156-9. Am J Med. 1995. PMID: 7653484

3

Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension.

Petitpretz P, Brenot F, Azarian R, Parent F, Rain B, Herve P, Simonneau G. Petitpretz P, et al. Among authors: herve p. Circulation. 1994 Jun;89(6):2722-7. doi: 10.1161/01.cir.89.6.2722. Circulation. 1994. PMID: 8205687

4

Primary pulmonary hypertension and fenfluramine use.

Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Brenot F, et al. Among authors: herve p. Br Heart J. 1993 Dec;70(6):537-41. doi: 10.1136/hrt.70.6.537. Br Heart J. 1993. PMID: 8280518 Free PMC article.

5

Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension.

Raffy O, Azarian R, Brenot F, Parent F, Sitbon O, Petitpretz P, Hervé P, Duroux P, Dinh-Xuan AT, Simonneau G. Raffy O, et al. Among authors: herve p. Circulation. 1996 Feb 1;93(3):484-8. doi: 10.1161/01.cir.93.3.484. Circulation. 1996. PMID: 8565165

6

Pulmonary vascular disorders in portal hypertension.

Hervé P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Hervé P, et al. Eur Respir J. 1998 May;11(5):1153-66. doi: 10.1183/09031936.98.11051153. Eur Respir J. 1998. PMID: 9648972 Free article. Review.

7

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G. Sitbon O, et al. Among authors: herve p. Eur Respir J. 1998 Aug;12(2):265-70. doi: 10.1183/09031936.98.12020265. Eur Respir J. 1998. PMID: 9727772 Free article.

8

Severe pulmonary hypertension in histiocytosis X.

Fartoukh M, Humbert M, Capron F, Maître S, Parent F, Le Gall C, Sitbon O, Hervé P, Duroux P, Simonneau G. Fartoukh M, et al. Among authors: herve p. Am J Respir Crit Care Med. 2000 Jan;161(1):216-23. doi: 10.1164/ajrccm.161.1.9807024. Am J Respir Crit Care Med. 2000. PMID: 10619823

9

Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension.

Provencher S, Hervé P, Sitbon O, Humbert M, Simonneau G, Chemla D. Provencher S, et al. Among authors: herve p. Eur Respir J. 2008 Aug;32(2):393-8. doi: 10.1183/09031936.00009008. Epub 2008 Apr 16. Eur Respir J. 2008. PMID: 18417516 Free article.

10

[Primary pulmonary artery hypertension (data of the literature and personal experience with 25 cases in 10 years)].

Brenot F, Hervé P, Rain B, Simonneau G. Brenot F, et al. Among authors: herve p. Rev Prat. 1991 Jun 11;41(17):1560-7. Rev Prat. 1991. PMID: 1853125 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

583 results

Search Page